Bosh sahifa084990 • KOSDAQ
add
Helixmith Co Ltd
Yopilish kursi
8 380,00 ₩
Kunlik diapazon
8 240,00 ₩ - 8 880,00 ₩
Yillik diapazon
2 115,00 ₩ - 9 220,00 ₩
Bozor kapitalizatsiyasi
393,17 mlrd KRW
Oʻrtacha hajm
528,37 ming
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
KOSDAQ
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (KRW) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 490,24 mln | -69,98% |
Joriy xarajat | 2,62 mlrd | 15,56% |
Sof foyda | 2,87 mlrd | 246,29% |
Sof foyda marjasi | 586,11 | 587,29% |
Har bir ulushga tushum | — | — |
EBITDA | -1,95 mlrd | -633,44% |
Amaldagi soliq stavkasi | — | — |
Balans
Jami aktivlari
Jami passivlari
| (KRW) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 81,70 mlrd | 7,35% |
Jami aktivlari | 143,20 mlrd | -3,82% |
Jami passivlari | 1,67 mlrd | -75,58% |
Umumiy kapital | 141,52 mlrd | — |
Tarqatilgan aksiyalar | 55,16 mln | — |
Narxi/balansdagi bahosi | 3,26 | — |
Aktivlardan daromad | -4,11% | — |
Kapitaldan daromad | -4,21% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (KRW) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 2,87 mlrd | 246,29% |
Operatsiyalardan naqd pul | -2,85 mlrd | -105,31% |
Sarmoyadan naqd pul | 32,76 mlrd | 2 268,43% |
Moliyadan naqd pul | -6,07 mln | -11,11% |
Naqd pulning sof oʻzgarishi | 29,88 mlrd | 8 319,84% |
Boʻsh pul | -5,91 mlrd | -191,51% |
Haqida
Helixmith Co. LTD. is a biotechnology company located in Seoul, South Korea with US presence in San Diego. The company has an extensive gene therapy pipeline, including a non-viral plasmid DNA program for neuromuscular and ischemic disease, a CAR-T program targeting several different types of solid tumors, and an AAV vector program targeting neuromuscular diseases. Helixmith’s lead gene is Engensis, currently in phase III diabetic peripheral neuropathy in the US. Engensis is a plasmid DNA designed to simultaneously express two isoforms of hepatocyte growth factor, HGF 728 and HGF 723. In addition to DPN, Engensis is also being studied in diabetic foot ulcers, amyotrophic lateral sclerosis, coronary artery disease, claudication, and Charcot-Marie-Tooth disease. Wikipedia
Tashkil etilgan
noy 1996
Sayt
Xodimlar soni
38
